Department of Pathology, The Cancer Hospital of the University of Chinese Academy of Sciences(Zhejiang Cancer Hospital), Hangzhou, PR China.
Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, PR China.
J Pathol. 2022 Aug;257(5):650-662. doi: 10.1002/path.5916. Epub 2022 May 20.
Tumor-infiltrating lymphocytes (TILs) offer a key for morphological diagnosis of lymphoepithelioma-like carcinoma (LELC) and are the foundation of oncoimmunology. To date, no reports have found a specific risk stratification value of TILs and related it to genomic variation in LELC. Based on the stromal TILs (str-TILs) ratio, we classified 105 Epstein-Barr virus (EBV)-associated LELC cases into two subtypes: patients with ≥60% str-TILs area ratio in tumor were classified as subtype I, and otherwise as subtype II. Subtype I patients had significantly better progression-free survival (PFS) and overall survival (OS). We also explored the genomic characteristics of EBV-associated LELC within different involved organs. We performed whole-exome sequencing for 51 patients with enough tissue and analyzed the genomic characteristics of EBV-associated LELC. Overall, EBV-associated LELCs were characterized by a low somatic mutation rate and copy number variations; the enriched genetic lesions affected RTK-RAS, PI3K, and cell cycle pathways. Moreover, EBV-associated LELCs from different organs were more similar to each other genetically as compared with other traditional carcinomas of the same sites-as evidenced by unsupervised clustering based on the quantitative data from both mutation signature and chromosomal aneuploidies. Notably, EBV-associated LELC patients with oncogenic driver alterations showed a worse prognosis compared with patients without such alterations. © 2022 The Pathological Society of Great Britain and Ireland.
肿瘤浸润淋巴细胞 (TILs) 为淋巴上皮瘤样癌 (LELC) 的形态学诊断提供了关键线索,是肿瘤免疫的基础。迄今为止,尚未有研究报道发现 TILs 的特定风险分层价值,并将其与 LELC 的基因组变异相关联。基于间质 TILs(str-TILs)比例,我们将 105 例 EBV 相关的 LELC 病例分为两亚型:肿瘤中 str-TILs 面积比≥60%的患者归入 I 型,否则归入 II 型。I 型患者的无进展生存期 (PFS) 和总生存期 (OS) 显著更好。我们还探索了不同受累器官中 EBV 相关的 LELC 的基因组特征。我们对 51 例有足够组织的患者进行了全外显子组测序,并分析了 EBV 相关的 LELC 的基因组特征。总体而言,EBV 相关的 LELC 具有较低的体细胞突变率和拷贝数变异;富集的遗传病变影响 RTK-RAS、PI3K 和细胞周期途径。此外,与其他传统的同一部位的癌相比,来自不同器官的 EBV 相关的 LELC 在遗传上更为相似——这一点可以从基于突变特征和染色体非整倍性的定量数据的无监督聚类中得到证明。值得注意的是,与无此类改变的患者相比,具有致癌驱动改变的 EBV 相关的 LELC 患者预后更差。